GlassScriptPhysician profile
Godfrey J Mark
NPI 1740442318
$9,697.01
in general payments reported to CMS, 2019-2025
46 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $769 · 2021: $2,290 · 2022: $1,216 · 2023: $1,660 · 2024: $1,481 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,848.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,541.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $1,449.57 | 2021 | |
| Abbvie INC. | $1,253.46 | 2021-2025 | |
| Lilly USA, LLC | $575.49 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $526.43 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $521.56 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $411.27 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Shield Therapeutics INC | $281.93 | 2022-2025 | Accrufer |
| Glaxosmithkline, LLC. | $273.58 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $252.51 | 2024-2025 | Caplyta |
| Amgen INC. | $240.34 | 2019-2025 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $239.35 | 2022-2025 | |
| Pfizer INC. | $210.16 | 2019-2025 | |
| Exact Sciences Corporation | $205.22 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $180.68 | 2020-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Godfrey Mark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.